Literature DB >> 10588260

Primary orbital angiosarcoma: a case report.

J D Siddens1, J R Fishman, I T Jackson, F A Nesi, K Tsao.   

Abstract

PURPOSE: The pathogenesis, natural history, histopathology, and recommended treatment for orbital angiosarcoma are illustrated and reviewed.
METHODS: Case report.
RESULTS: A 71-year-old white male presented with bluish discoloration and swelling of the left medial canthal area. A fine needle aspiration and excisional biopsy with histopathologic examination was performed, which showed angiosarcoma. Pattern of growth was demonstrated radiographically and histopathologically, confirming primary orbital angiosarcoma. Subsequent wide surgical resection was carried out, with substantial reconstruction of the left orbital and periorbital area. The patient responded well to the surgery, and was free of tumor after six years of follow-up.
CONCLUSION: Angiosarcoma is a rare and highly malignant tumor of epithelial origin. The aggressive nature of this tumor usually results in a high mortality rate despite treatment. However, early diagnosis and wide surgical excision has resulted in successful treatment of these tumors.

Entities:  

Mesh:

Year:  1999        PMID: 10588260     DOI: 10.1097/00002341-199911000-00019

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  3 in total

1.  Two Cases of Angiosarcoma with Persistent Unilateral Eyelid Swelling.

Authors:  Shinzo Sakisaka; Mika Tanabe; Shuhei Imayama; Nahoko Zeze; Kanako Yamana; Hiroshi Yoshikawa; Koh-Hei Sonoda
Journal:  Ocul Oncol Pathol       Date:  2021-10-21

Review 2.  Rare Diseases of the Orbit.

Authors:  Ulrich Kisser; Jens Heichel; Alexander Glien
Journal:  Laryngorhinootologie       Date:  2021-04-30       Impact factor: 1.057

3.  High grade angiosarcoma arising in fibroadenoma.

Authors:  Emina Babarović; Gordana Zamolo; Elvira Mustać; Miroslav Strčić
Journal:  Diagn Pathol       Date:  2011-12-20       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.